Guillain-Barré Syndrome (GBS) is a rare but serious neurological disorder in which the body’s immune system mistakenly attacks the peripheral nerves — the network that connects the brain and spinal cord to the rest of the body.

This immune response leads to inflammation and damage to the myelin sheath, the protective covering around the nerves, which disrupts the transmission of nerve signals.

The result is weakness, numbness, and sometimes paralysis that typically begins in the legs and moves upward through the body.

Although rare, GBS may develop after vaccination. This can happen when the body’s immune response to the vaccine mistakenly targets nerve tissue.

Vaccines are designed to trigger the immune system to produce protective antibodies, but this immune reaction can “cross-react” with components of the peripheral nerves.

Scientists believe this occurs because some vaccine antigens may share structural similarities with molecules found in nerve cells. This is known as molecular mimicry theory.

When that happens, the immune system cannot always distinguish between the vaccine target and the body’s own nerve tissue, leading to inflammation and demyelination.

Early symptoms of GBS often include tingling sensations, muscle weakness, or a “pins and needles” feeling in the feet or hands.

Within days or weeks, this weakness can spread to the arms and upper body. In severe cases, the muscles that control breathing can become paralyzed, making hospitalization and mechanical ventilation necessary.

Reflexes, such as knee-jerk responses, are often lost, and pain or difficulty walking may occur. Although most people eventually recover, the progression of symptoms can be frightening and rapid, often reaching peak severity within two to four weeks.

Treatment for Guillain-Barré Syndrome focuses on reducing the immune system’s attack and supporting the body through recovery.

Two primary treatments are used: intravenous immunoglobulin (IVIG) and plasma exchange (plasmapheresis).

Both therapies aim to remove or neutralize the antibodies attacking the nerves. Physical therapy is often essential to help rebuild strength and coordination as patients recover.

Recovery can take weeks to months, and some individuals may experience lasting weakness, numbness, or fatigue.

GBS affects approximately 1 to 2 people per 100,000 each year in the United States.

While most cases occur after infections like influenza or gastrointestinal illness, GBS can also, in rare cases, result from a vaccination.

Statistically, the VICP has achieved around 1.2 awards per million vaccine doses administered. Of these, about 55% are shoulder injury claims, and a smaller percentage (sometimes about 25%) are GBS claims.

The majority of GBS patients (often about 70%) recover fully. About 5% of GBS patients may not survive due to complications. About 25% of GBS patients suffer with long-lasting or permanent weakness or disability.

Please keep in mind, every body and every injury is unique. These are broad statistics that may or may not apply in any specific case.

Settlements for GBS injuries are often over $100,000.

And remember: any settlement that we secure for you is 100% yours. Our attorney fees and expenses are paid in a second, unrelated payment that the court will compensate later.